A Phase 2, Multi-Center, Randomized, Double-Masked, Saline-Controlled Study to Evaluate the Effect of Perfluorohexyloctane (NOV03) at Two Different Dosing Regimens on Signs and Symptoms of Dry Eye Disease (DED)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 02 Apr 2018
At a glance
- Drugs Perfluorohexyloctane (Primary)
- Indications Dry eyes
- Focus Therapeutic Use
- Acronyms SEECASE
- Sponsors Novaliq
- 29 Mar 2018 Planned primary completion date changed from 1 Jul 2018 to 1 May 2018.
- 29 Mar 2018 Status changed from recruiting to active, no longer recruiting.
- 08 Jan 2018 According to a Novaliq media release, randomization of patients has been begun for this trial.